Atlas Trials

Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation

RecordFirmDate
A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting (NCT04967248)Novartis Pharmaceuticals2023-06-21

Track Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation automatically

Every clearance here is in the API, with alerts when new ones post.